The Jessa Hospital experience for cardiac rehabilitation
The ESC and EAPC reference centre for cardiac rehabilitation presents its accelerated programme for cardiac rehabilitation brought about by COVID-19 (Source: European Heart Journal)
Source: European Heart Journal - April 14, 2021 Category: Cardiology Source Type: research

Old and new enemies: psychological stress, occupational stress, COVID-19, and a glimpse of the future
(Source: European Heart Journal)
Source: European Heart Journal - April 14, 2021 Category: Cardiology Source Type: research

A call to action for new global approaches to cardiovascular disease drug solutions
AbstractWhilst we continue to wrestle with the immense challenge of implementing equitable access to established evidence-based treatments, substantial gaps remain in our pharmacotherapy armament for common forms of cardiovascular disease including coronary and peripheral arterial disease, heart failure, hypertension, and arrhythmia. We need to continue to invest in the development of new approaches for the discovery, rigorous assessment, and implementation of new therapies. Currently, the time and cost to progress from lead compound/product identification to the clinic, and the success rate in getting there reduces the in...
Source: European Heart Journal - April 13, 2021 Category: Cardiology Source Type: research

The physical activity paradox in cardiovascular disease and all-cause mortality: the contemporary Copenhagen General Population Study with 104  046 adults
Conclusion  Higher leisure time physical activity associates with reduced MACE and all-cause mortality risk, while higher occupational physical activity associates with increased risks, independent of each other. (Source: European Heart Journal)
Source: European Heart Journal - April 9, 2021 Category: Cardiology Source Type: research

Prevention of cardiovascular disease: does ‘every step counts’ apply for occupational work?
(Source: European Heart Journal)
Source: European Heart Journal - April 9, 2021 Category: Cardiology Source Type: research

To stent or not to stent? Treating angina after ISCHEMIA —the impact of the ISCHEMIA trial on the indications for angiography and revascularization in patients with stable coronary artery disease
The ISCHEMIA trial is a large, multinational trial sponsored by the National Heart, Lung, and Blood Institute, which has recently been published.1 The main trial compares coronary revascularization and optimal medical therapy (OMT) vs. OMT alone in 5179 patients enrolled after stress testing, in addition to two ancillary studies in patients with chronic kidney disease (777 patients)2 and a quality of life sub-study in the main ISCHEMIA trial, which enrolled 4617 patients.3Crucial to placing the results of this important trial into perspective is a review of where we stood prior to the publication of ISCHEMIA, in regard to ...
Source: European Heart Journal - April 7, 2021 Category: Cardiology Source Type: research

Dr Raphael Twerenbold
In an EHJ CardioPulse series looking at the next generation of leaders in cardiology, Mark Nicholls speaks to Dr Raphael Twerenbold about his clinical and research focus (Source: European Heart Journal)
Source: European Heart Journal - April 7, 2021 Category: Cardiology Source Type: research

Guidelines on myocardial infarction, novel therapeutic targets in post-infarction remodelling, and a debate on the ISCHEMIA trial
(Source: European Heart Journal)
Source: European Heart Journal - April 7, 2021 Category: Cardiology Source Type: research

Interleukin-1 blockade: a paradigm shift in the treatment of patients with recurrent pericarditis?
Comment on “Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis”, which was presented at the American Heart Association 2020 Scientific Sessions and published in the New England Journal of Medicine (https://doi.org/10.1056/NEJMoa2027892) (Source: European Heart Journal)
Source: European Heart Journal - April 7, 2021 Category: Cardiology Source Type: research

To stent or not to stent? Treating angina after ISCHEMIA —introduction
(Source: European Heart Journal)
Source: European Heart Journal - April 7, 2021 Category: Cardiology Source Type: research

To stent or not to stent? Treating angina after ISCHEMIA —why a conservative approach with optimal medical therapy is the preferred initial management strategy for chronic coronary syndromes: insights from the ISCHEMIA trial
(Source: European Heart Journal)
Source: European Heart Journal - April 7, 2021 Category: Cardiology Source Type: research

Decoding stroke risk scores in atrial fibrillation: still more work to do
(Source: European Heart Journal)
Source: European Heart Journal - April 6, 2021 Category: Cardiology Source Type: research

Dapagliflozin, advanced chronic kidney disease, and mortality: new insights from the DAPA-CKD trial
(Source: European Heart Journal)
Source: European Heart Journal - April 1, 2021 Category: Cardiology Source Type: research

Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial
Conclusion  In patients with CKD, dapagliflozin prolonged survival irrespective of baseline patient characteristics. The benefits were driven largely by reductions in non-cardiovascular death. (Source: European Heart Journal)
Source: European Heart Journal - April 1, 2021 Category: Cardiology Source Type: research

Challenges in heart failure: quality of life, chronic kidney disease, and secondary mitral regurgitation
(Source: European Heart Journal)
Source: European Heart Journal - April 1, 2021 Category: Cardiology Source Type: research

Erratum to: “ESC Core Curriculum for the Cardiologist”
Upon the original publication of this correction notice, the following requested author corrections to the original article “’ESC Core Curriculum for the Cardiologist’ Felix C Tanner, Nicolas Brooks, Kevin F Fox, Lino Gonçalves, Peter Kearney, Lampros Michalis, Agnès Pasquet, Susanna Price, Eric Bonnefoy, Mark Westwood, Chris Plummer, Paulus Kirchhof, ESC Scientific Document GroupEuropean Heart Journal, Volume 41, Issue 38, 7 October 2020, Pages3605 –3692,https://doi.org/10.1093/eurheartj/ehaa641”, were inadvertently not listed and not made. The Publisher would like to apologize ...
Source: European Heart Journal - March 31, 2021 Category: Cardiology Source Type: research

Validation of risk scores for ischaemic stroke in atrial fibrillation across the spectrum of kidney function
AbstractAims  The increasing prevalence of ischaemic stroke (IS) can partly be explained by the likewise growing number of patients with chronic kidney disease (CKD). Risk scores have been developed to identify high-risk patients, allowing for personalized anticoagulation therapy. However, predictive performance in CKD is unclear. The aim of this study is to validate six commonly used risk scores for IS in atrial fibrillation (AF) patients across the spectrum of kidney function.Methods and results  Overall, 36  004 subjects with newly diagnosed AF from SCREAM (Stockholm CREAtinine Measurements), a healthcare...
Source: European Heart Journal - March 26, 2021 Category: Cardiology Source Type: research

Jiri Widimsky MD
(Source: European Heart Journal)
Source: European Heart Journal - March 25, 2021 Category: Cardiology Source Type: research

Handling time elements for in-hospital cardiac arrest
(Source: European Heart Journal)
Source: European Heart Journal - March 23, 2021 Category: Cardiology Source Type: research

In-hospital resuscitation of Covid-19 patients is impeded by serious delays, but the problem is obscured by poor time data
This commentary refers to ‘Cardiac arrest in COVID-19: characteristics and outcomes of in- and out-of-hospital cardiac arrest. A report from the Swedish Registry for Cardiopulmonary Resuscitation’, by P. Sultanianet al., doi:10.1093/eurheartj/ehaa1067 and the discussion piece ‘Handling time elements for in-hospital cardiac arrest’, by P. Sultanianet al., doi:10.1093/eurheartj/ehaa163. (Source: European Heart Journal)
Source: European Heart Journal - March 23, 2021 Category: Cardiology Source Type: research

New therapeutic targets in lipid lowering: high-sugar feeding in infants, lipoprotein(a), and lipoprotein lipase
(Source: European Heart Journal)
Source: European Heart Journal - March 21, 2021 Category: Cardiology Source Type: research

The management of secondary mitral regurgitation in patients with heart failure: a joint position statement from the Heart Failure Association (HFA), European Association of Cardiovascular Imaging (EACVI), European Heart Rhythm Association (EHRA), and European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC
AbstractSecondary (or functional) mitral regurgitation (SMR) occurs frequently in chronic heart failure (HF) with reduced left ventricular (LV) ejection fraction, resulting from LV remodelling that prevents coaptation of the valve leaflets. Secondary mitral regurgitation contributes to progression of the symptoms and signs of HF and confers worse prognosis. The management of HF patients with SMR is complex and requires timely referral to a multidisciplinary Heart Team. Optimization of pharmacological and device therapy according to guideline recommendations is crucial. Further management requires careful clinical and imagi...
Source: European Heart Journal - March 18, 2021 Category: Cardiology Source Type: research

Past and future of channelopathies and a focus on cardiac arrest
(Source: European Heart Journal)
Source: European Heart Journal - March 14, 2021 Category: Cardiology Source Type: research

The value of sotagliflozin in patients with diabetes and heart failure detracted by an unexpected ending
Comment on ‘Sotagliflozin in patients with diabetes and recent worsening heart failure’ published in theNew England Journal of Medicine, doi:10.1056/NEJMoa2030183.Key Points (Source: European Heart Journal)
Source: European Heart Journal - March 10, 2021 Category: Cardiology Source Type: research

The association between coronary graft patency and clinical status in patients with coronary artery disease
AbstractThe concept of a direct association between coronary graft patency and clinical status is generally accepted. However, the relationship is more complex and variable than usually thought. Key issues are the lack of a common definition of graft occlusion and of a standardized imaging protocol for patients undergoing coronary bypass surgery. Factors like the type of graft, the timing of the occlusion, and the amount of myocardium at risk, as well as baseline patients ’ characteristics, modulate the patency-to-clinical status association. Available evidence suggests that graft occlusion is more often associated w...
Source: European Heart Journal - March 8, 2021 Category: Cardiology Source Type: research

Silent brain infarction after TAVR: common but of unclear significance
This editorial refers to ‘Silent brain infarcts and early cognitive outcomes after transcatheter aortic valve implantation: a systematic review and meta-analysis’††, by K. Woldendorpet al., on page1004. (Source: European Heart Journal)
Source: European Heart Journal - March 7, 2021 Category: Cardiology Source Type: research

Challenges in interventional cardiology: embolic complications, cancer patients, and duration of antithrombotic therapy
(Source: European Heart Journal)
Source: European Heart Journal - March 7, 2021 Category: Cardiology Source Type: research

Ischaemic and bleeding risk in cancer patients undergoing PCI: another brick in the wall
(Source: European Heart Journal)
Source: European Heart Journal - March 3, 2021 Category: Cardiology Source Type: research

Percutaneous coronary intervention in patients with cancer and readmissions within 90 days for acute myocardial infarction and bleeding in the USA
ConclusionsFollowing PCI, patients with cancer have increased risk for readmissions for AMI or bleeding, with the magnitude of risk depending on both cancer type and the presence of metastasis. (Source: European Heart Journal)
Source: European Heart Journal - March 3, 2021 Category: Cardiology Source Type: research

How inflammation heats the heart
(Source: European Heart Journal)
Source: European Heart Journal - March 1, 2021 Category: Cardiology Source Type: research

A randomized trial supports the recommendation to continue treatment with ACEi or ARBs during hospitalization for COVID-19
Comment on “Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19” published inJAMA (doi:10.1001/jama.2020.25864) (Source: European Heart Journal)
Source: European Heart Journal - February 28, 2021 Category: Cardiology Source Type: research

All-cause mortality and location of death in patients with established cardiovascular disease before, during, and after the COVID-19 lockdown: a Danish Nationwide Cohort Study
ConclusionsAmong patients with established cardiovascular disease, the in-hospital mortality rate was lower and out-of-hospital mortality rate higher during lockdown compared with the same period in the preceding year, irrespective of age and sex. (Source: European Heart Journal)
Source: European Heart Journal - February 24, 2021 Category: Cardiology Source Type: research

The collateral cardiovascular damage of COVID-19: only history will reveal the depth of the iceberg
(Source: European Heart Journal)
Source: European Heart Journal - February 24, 2021 Category: Cardiology Source Type: research

Glucocorticoids in patients with immune-mediated inflammatory diseases: a neglected cardiovascular risk factor
Comment on “Dose-dependent oral glucocorticoid cardiovascular risks in people with immunemediated inflammatory diseases: a population-based cohort study” is available onPLoS Medicine (Source: European Heart Journal)
Source: European Heart Journal - February 22, 2021 Category: Cardiology Source Type: research

Is coronary flow velocity reserve just a marker of a higher atherosclerotic burden?
This commentary refers to the article ‘Coronary flow velocity reserve predicts adverse prognosis in women with angina and no obstructive coronary artery disease: results from the iPOWER study’, by J. Schroderet al., doi:10.1093/eurheartj/ehaa944 and the discussion piece ‘Coronary flow velocity reserve adds prognostic information beyond presence or absence of non-obstructive coronary atherosclerosis’, by J. Schroder and E. Prescott, doi:10.1093/eurheartj/ehab064. (Source: European Heart Journal)
Source: European Heart Journal - February 17, 2021 Category: Cardiology Source Type: research

Coronary flow velocity reserve adds prognostic information beyond presence or absence of non-obstructive coronary atherosclerosis
This commentary refers to the article ‘Coronary flow velocity reserve predicts adverse prognosis in women with angina and no obstructive coronary artery disease: results from the iPOWER study’, by J. Schroderet al., doi:10.1093/eurheartj/ehaa944 and the discussion piece ‘Is coronary flow velocity reserve just a marker of a higher atherosclerotic burden?’, by F. Radicoet al., doi:10.1093/eurheartj/ehab062. (Source: European Heart Journal)
Source: European Heart Journal - February 17, 2021 Category: Cardiology Source Type: research

Quality of life in EMPEROR-Reduced: emphasizing what is important to patients while identifying strategies to support more patient-centred care
(Source: European Heart Journal)
Source: European Heart Journal - February 17, 2021 Category: Cardiology Source Type: research

Common modulators of Brugada syndrome phenotype do not affect SCN5A prognostic value
This commentary refers to the article ‘Brugada syndrome genetics is associated with phenotype severity’ by G. Ciconteet al., doi:10.1093/eurheartj/ehaa942 and the discussion piece ‘Different genotypes of Brugada syndrome may present different clinical phenotypes: electrophysiology from bench to bedside’ by I El-Battrawyet al., doi:10.1093/eurheartj/ehab070. (Source: European Heart Journal)
Source: European Heart Journal - February 17, 2021 Category: Cardiology Source Type: research

Different genotypes of Brugada syndrome may present different clinical phenotypes: electrophysiology from bench to bedside
This commentary refers to ‘Brugada syndrome genetics is associated with phenotype severity’ by G. Ciconteet al., doi:10.1093/eurheartj/ehaa942 and the discussion piece ‘Common modulators of Brugada syndrome phenotype do not affect SCN5A prognostic value’ by C. Papponeet al., doi:10.1093/eurheartj/ehab071. (Source: European Heart Journal)
Source: European Heart Journal - February 17, 2021 Category: Cardiology Source Type: research

A broken heart after child loss
(Source: European Heart Journal)
Source: European Heart Journal - February 15, 2021 Category: Cardiology Source Type: research

Corrigendum to: Procedural myocardial injury, infarction and mortality in patients undergoing elective PCI: a pooled analysis of patient-level data
In the originally published version of this manuscript, errors were noted and listed in this corrigendum. (Source: European Heart Journal)
Source: European Heart Journal - February 15, 2021 Category: Cardiology Source Type: research

PCSK9 inhibition: Not just LDL-Cholesterol knock down: A glimmer for cancer
Comment on “Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer” which was published in Nature, doi:10.1038/s41586-020-2911-7. (Source: European Heart Journal)
Source: European Heart Journal - February 15, 2021 Category: Cardiology Source Type: research

Corrigendum to: The year in cardiovascular medicine 2020: heart failure and cardiomyopathies
[Eur Heart J 2021:doi:10.1093/eurheartj/ehaa1061] (Source: European Heart Journal)
Source: European Heart Journal - February 11, 2021 Category: Cardiology Source Type: research

Re-purposed antiviral drugs without a purpose in COVID-19: a valuable lesson for clinicians
Comment on the interim results of the WHO Solidarity Trial, which were published in theNew England Journal of Medicine (DOI: 10.1056/NEJMoa2023184) (Source: European Heart Journal)
Source: European Heart Journal - February 11, 2021 Category: Cardiology Source Type: research

Unfolding and disentangling coronary vascular disease through genome-wide association studies
This editorial refers to ‘Genome-wide analysis identifies novel susceptibility loci for myocardial infarction’††, by J. Hartialaet al., on page919. (Source: European Heart Journal)
Source: European Heart Journal - February 9, 2021 Category: Cardiology Source Type: research

Xenotransplantation in the era of a zoonotic pandemic
(Source: European Heart Journal)
Source: European Heart Journal - February 8, 2021 Category: Cardiology Source Type: research

When less is more: dual antiplatelet therapy in elective percutaneous coronary intervention
Comment on ‘Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial’, which was presented at the 2020 Scientific Sessions of the American Heart Association and published in The Lancet (doi.org/10.1016/S0140-6736(20)32236-4). (Source: European Heart Journal)
Source: European Heart Journal - February 8, 2021 Category: Cardiology Source Type: research

Corrigendum to: Predicted Benefit of an Implantable Cardioverter-Defibrillator: The MADIT-ICD Benefit Score
In the originally published version of this manuscript, the author list indicated that First-author Arwa Younis was also the corresponding author. The corresponding author should be Ilan Goldenberg. This error has now been corrected online. (Source: European Heart Journal)
Source: European Heart Journal - February 7, 2021 Category: Cardiology Source Type: research

Cardiac arrest occurrence during successive waves of the COVID-19 pandemic: direct and indirect consequences
(Source: European Heart Journal)
Source: European Heart Journal - February 5, 2021 Category: Cardiology Source Type: research

Cardiac arrest in COVID-19: characteristics and outcomes of in- and out-of-hospital cardiac arrest. A report from the Swedish Registry for Cardiopulmonary Resuscitation
ConclusionDuring the pandemic phase, COVID-19 was involved in at least 10% of all OHCAs and 16% of IHCAs, and, among COVID-19 cases, 30-day mortality was increased 3.4-fold in OHCA and 2.3-fold in IHCA. (Source: European Heart Journal)
Source: European Heart Journal - February 5, 2021 Category: Cardiology Source Type: research